Evaluation of <scp>GABAergic</scp> and Glutamatergic Levels in the Dorsal Anterior Cingulate Cortex of Patients With Bipolar Disorder: A Cross‐Sectional <scp> <sup>1</sup> H </scp> ‐ <scp>MRS</scp> Study
Our results suggest that GABAergic function in the dACC may not play a pivotal role in the pathophysiology of BD. Given possible GABAergic dysregulation in BD, further research using alternative methodologies is warranted to elucidate the pathological basis.
Authors
- M. Mimura
- Mié Matsui (ORCID: https://orcid.org/0000-0003-0785-4351)
- Koki Takahashi (ORCID: https://orcid.org/0000-0003-4542-3747)
- Keita Taniguchi
- Yoshihiro Noda (ORCID: https://orcid.org/0000-0002-2155-0357)
- H. Uchida
- Sunjun Huh
- Masataka Wada (ORCID: https://orcid.org/0000-0002-3937-3619)
- Shinsuke Koike (ORCID: https://orcid.org/0000-0002-3375-236X)
- Sotaro Moriyama
- Yui Tobari
- Shiori Honda (ORCID: https://orcid.org/0000-0002-3756-0584)
- Richard A E Edden
- Saki Homma
- Keisuke Saito
- Shinichiro Nakajima
- Sakiko Tsugawa
- Yumina Nakane
Institutions
- Kanazawa University (JP)
- Kennedy Krieger Institute (US)
- Johns Hopkins University (US)
- Tokyo University of the Arts (JP)
- Keio University (JP)
- Stony Brook School (US)
- Keio University Shonan Fujisawa (JP)
- Mita Hospital (JP)
- Yokohama City University (JP)
- Stanford University (US)
Publication Details
- Journal
- Neuropsychopharmacology Reports
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1002/npr2.70085
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Research Foundation for Clinical Pharmacology
- Japan Agency for Medical Research and Development
- Astellas Pharma
- SENSHIN Medical Research Foundation
- Teijin Pharma
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Moonshot Research and Development Program
- Daiichi Sankyo Europe